Skip to content
Search

Latest Stories

Wolverhampton lab suspended after 'incorrect' Covid-19 test results

A Covid-19 testing laboratory, Wolverhampton in central England has been suspended over concern that it has been incorrectly giving negative PCR test results to people who are infected, the UK Health Security Agency (UKHSA) said today (Oct 15).

NHS Test and Trace launched an investigation into a lab in Wolverhampton after reports of people getting negative PCR test results after testing positive on rapid lateral flow devices (LFDs).


Government advice says PCR tests are more accurate than LFDs, and people can stop self-isolating if a positive LFD result is followed by a negative PCR test result.

UKSHA said that an estimated 43,000 people may have been given incorrect negative PCR test results, mainly in South West England, possibly underestimating the number of people with coronavirus between September 8 and October 12.

"We have immediately suspended testing at this laboratory while we continue the investigation," said Dr Will Welfare, public health incident director at UKSHA.

"There is no evidence of any faults with LFD or PCR test kits themselves and the public should remain confident in using them and in other laboratory services currently provided."

Immensa Health Clinic, who run the lab, said they were "fully collaborating" with UKSHA in the investigation.

UKSHA said it was an isolated incident in one laboratory, with samples now being redirected to other labs.

It added the Immensa lab was only a small part of the national network, so overall testing availability was unaffected, and people with a positive LFD test result should continue to get it confirmed with a PCR.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less